heading · body

Stock · INDIGOPNTS · Indian Paints

Indigo Paints — the man, the layer, the choice he keeps making

Indigo Paints Limited

period FY25 + Q3 FY26 added 2026-04-26 score 7/10
equity-research paints india INDIGOPNTS

Indigo Paints — the man, the layer, the choice he keeps making

On the Q3 FY26 concall in late January 2026, a sell-side analyst — patient, polite, the kind of voice that has been on these calls for the better part of a decade — asked Hemant Jalan how he planned to defend market share against Birla Opus through the next twelve months. Jalan is 65. He owns 53.88% of the company that sat on his screen. He has been running it for twenty-five years. He had, by that point in the call, already made the case three different ways that the new entrant’s threat had been overestimated by analysts and absorbed by incumbents. And then, almost throwaway, he said: “Why should we not think of going even more aggressively on trade discounts and maybe sacrifice a percentage point from our gross margin — we’ll still be the highest.”

It was the answer of a man who knows the shape of his own balance sheet. Indigo’s standalone gross margin in that quarter was 47.1% — the highest in the listed peer set. Asian Paints, post-derate, was running 41-43%. Berger around 40%. Jalan was saying, in effect: I can give up a point of margin to defend dealer mindshare and I will still walk out of the fight with the fattest gross margin in the industry. It was the small player’s leverage in reverse — when you start with the most cushion, you have the most room to spend it before it hurts. The line is the entire investment debate compressed into thirty words.

To understand why he is able to say it that way, you have to go back to a calcium chloride factory in Patna in 1999.

The 1999 quit

Hemant Jalan was, for most of the 1990s, the kind of CV that Indian conglomerates collect and rotate through their heavier industrial assets. Chemical engineering at IIT Delhi. A graduate degree at UC Berkeley. A return to India and a long stretch at what was then Sterlite Industries — the Vedanta group’s metals arm — where he ended up running the copper smelter unit at Tuticorin. It was a serious posting. The Tuticorin smelter was one of the largest single-site copper refineries in Asia at the time, and the unit head was responsible for a few thousand tonnes a day of cathode output and a workforce that ran in the four figures.

In 1999 he quit. He went home and started a calcium chloride factory in Patna. Calcium chloride is the white desiccant powder you find in shoe boxes and salt shakers in humid climates — about as far from copper smelting as you can get inside the boundaries of the periodic table. The Patna unit was small. By the standards of someone who had been running a smelter, it was something close to an act of voluntary descent.

A year later, in 2000, he moved further down the same arc and started a small paint business out of Jodhpur with Rs 1 lakh of capital. Not Mumbai, not Bangalore, not even Pune. Jodhpur. The choice mattered. By 2000 the Indian paints market was already a structurally consolidated category — Asian Paints had a third of it, Berger and Kansai shared most of the rest, the smaller regional brands were either being squeezed out or quietly bought up. The way to start a paint company against that backdrop was either to raise serious capital and buy distribution, or to start somewhere none of the incumbents particularly cared about and make a margin per litre that justified a slow walk outward. Jalan had no capital. He chose Jodhpur.

For the next fourteen years Indigo was a bootstrapped operation. Internal cash flow plus bank debt, ploughed back into more SKUs and more dealers. It is easy, in retrospect, to glamourise this kind of grind. The actual texture of it was probably fairly grim — moving outward from Rajasthan into MP and Bihar one district at a time, hand-selling differentiated SKUs to dealers who had never heard of the brand, persuading retailers to stock a paint with no advertising budget against an Asian Paints display that came with a free tinting machine and a calendar of trade incentives. It worked because the SKUs were strange enough that the dealer could mark them up without competitive reference, and because Jalan, by all accounts, made the unit economics fair to the dealer rather than aggressive. The pitch settled into something like: we will give you a better margin than anyone else stocks you, and we will bring you products the majors will not bother pushing your way. That pitch has held for fifteen years.

Sequoia put in Rs 50 cr in 2014 — the first material outside capital the business had taken. It was used not for distribution arms-race spending but for capacity and brand investment in a still-conservative geographic perimeter. The IPO in January 2021 priced at Rs 1,490 a share, which valued the business at something close to Rs 7,000 cr — a kind of euphoric peak for paints multiples and for the IPO market generally. The stock has done nothing since. Fifteen quarters in, it traded around Rs 860 in late April 2026, having gone roughly nowhere. The business, meanwhile, has compounded revenue at a single-digit-to-low-double-digit rate and built out a Rs 1,341 cr (FY25 consolidated) revenue base. The disconnect is partly the multiple compression you would expect at any small-cap that listed at the top of a cycle, and partly the slow-burn nervousness about Birla Opus, about which more shortly.

What Jalan draws from the company in salary, by the way, is Rs 2.4 cr a year (FY24 disclosure). Under 4% of FY24 PAT. By the standard of Indian promoters at this scale of holding — 53.88% of the equity — that is spartan. He does not have a Goa hotel paid for by the company. There is no acquired land bank. The capital allocation reads as that of someone who genuinely thinks of the business as a long-term compounder rather than an exit vehicle, and who, given that he is past 65, is increasingly unusual in not having visibly begun to wind down.

The strategy that the SKU shelf reveals

Walk into a hardware store in Sikar, Rajasthan, or Begusarai, Bihar, and ask the dealer what he stocks of Indigo’s that he doesn’t stock from Asian Paints. The answers will tend to come back as a list of categories that the majors either don’t make or don’t bother promoting. Metallic emulsion — the bronzy or silvery wall finish you see in hotel bars and aspirational living rooms in homes where someone has recently watched a renovation video on YouTube. Tile coat emulsion — paint that bonds onto ceramic tiles and lets a homeowner refurbish a kitchen without ripping out the dado. Floor paint — the tough thing you put on garage floors and warehouse epoxies. A ceiling paint specifically formulated to not splash when you roll it. Bright-shade distempers in a market where Tier-3 and Tier-4 customers historically used drab colours because that was what was available.

This is the heart of the differentiated-SKU strategy that Jalan ran from day one. The reason it works is mathematical rather than mysterious. A category like floor paint or tile coat emulsion is a Rs 50-100 cr opportunity in any given year — too small to register as growth on Asian Paints’ Rs 35,000 cr revenue base. APL doesn’t make the SKU because the cost of formulating it, distributing it, and marketing it doesn’t justify the contribution to the consolidated P&L. Indigo, on a Rs 1,300 cr base, can make that same SKU and have it move the needle. The unit economics are fine because the customer pays a brand premium — there’s no lookalike on the next shelf to anchor the price down. Roughly thirteen new products were introduced between FY21 and FY24, and the pipeline continues to be the operating cadence of the business.

The product mix as of the FY24 disclosure tells the story slightly more bluntly. Cement paints and putty, the rural exterior segment, are 43-47% of revenue. Enamels and wood coatings are 22-24%. Primers, distempers, and others are 17-20%. Emulsions — the high-margin segment Birla Opus has gone to war in — are about 16% of revenue. That last number is worth holding onto. Of all the listed peers, Indigo has the lowest revenue exposure to the segment Birla is most aggressive in. The shelf war is not, for the most part, being fought on Indigo’s main shelves.

The geographic concentration is the other half of the same idea. Jalan deliberately did not start in Mumbai or Bangalore. Jodhpur first, then Rajasthan, then progressively outward. By December 2025 Indigo had 19,134 active dealers, which sounds tiny next to APL’s roughly 70,000 and Birla’s roughly 50,000. But the dealer footprint is geographically idiosyncratic — heavy in Rajasthan, MP, Bihar, eastern UP, smaller-town Karnataka and Andhra. In those geographies, places where APL is present but not dominant and where Berger and Kansai are thinner still, Indigo can credibly claim to be the second or third dealer-mindshare brand. The standard sector lens reads 19,134 against 70,000 and concludes that Indigo has a quarter of the relevant distribution. It doesn’t. It has a much narrower but locally meaningful slice in second-India geographies that the other three are not built around.

The Birla overlap question, in three concalls

The most interesting reading of FY26 is not the numbers — those are mid-single-digit growth, fine — but the way Hemant Jalan talked about Birla Opus across three quarterly concalls, and what that progression reveals.

In May 2025, on the Q1 FY26 call, the framing was defensive but confident. The prediction of outsiders, Jalan said, was that Birla’s entry would devastate the margins of the paint industry. He and the other paint CEOs had collectively been saying that this was not going to happen. Everyone’s gross margin was more or less the same as it had been a year or eighteen months ago. The apocalypse, he was effectively saying, was not coming. By November 2025, the same theme had sharpened. “New player is now stagnating,” Jalan said on the Q2 FY26 call. “They were taking a 5%, 6% market share in the first year. Now they are more of a status quo.” He noted, also, that Birla’s “extra grammage in smaller cans” promotion had been quietly discontinued — Birla itself was starting to retreat from its most aggressive opening moves. Indigo’s response on dealer schemes, he said, was to tailor the schemes to what each dealer actually wanted, sometimes paying in kind rather than cash, the explicit logic being to avoid getting drawn into a margin race they could not win on absolute spend.

By January 2026, on the Q3 FY26 call, he was almost vindicated. “Time has borne itself out that we were right. Nobody’s profitability has been impacted. Yes, a new entrant may have taken some market share at a significant cost to itself — that is their business.” And then the line that closes the loop on the strategy: “Why should we not think of going even more aggressively on trade discounts and maybe sacrifice a percentage point from our gross margin — we’ll still be the highest.”

Read together, this is the arc of a founder who was right early and is doubling down on having been right. The intellectual honesty cuts both ways, though. Jalan’s words conceal the part of the story that isn’t going his way. Birla’s roughly 50,000 dealers and 45,000 tinting machines didn’t materialise out of nothing — Birla bought them with capital, by making the unit economics for new dealers attractive enough to walk away from existing relationships. The dealer relationship sits on three legs: margin to the dealer, tinting-machine availability, and breadth of SKU. Birla’s offer beats Indigo on all three. So far the data says Indigo’s dealer count is still slowly growing — 18,371 in March 2025, 18,900 in September 2025, 19,134 in December 2025 — and gross margin has held. But that is a steady state read on a Birla that was burning cash through its first-year launch and whose outgoing CEO was in transition. New CEO Anubhav Sahay joined from ITC in January 2026. If he reaccelerates dealer-acquisition spending, the test on Indigo’s dealer count and gross margin will come in FY27, not FY26.

Indigo’s tinting-machine count is roughly 11,900 — less than a quarter of Birla’s 45,000. The free-tinting-machine giveaway is the dealer-acquisition moat-breaker that Birla has been using: drop a Rs 8-10 lakh machine on a dealer’s counter for free, and the dealer is now structurally hooked into Birla’s SKU ecosystem because the machine reads Birla’s colour formulae. Indigo has added only about 250 net machines between September and December 2025. They cannot afford to flood machines the way Birla did because the balance sheet equity is roughly Rs 1,000 cr, not the Aditya Birla Group’s. This is the structural gap that the bullish reading of Indigo’s franchise has to live with. So far it hasn’t bitten because Indigo’s dealers want Indigo’s specific high-margin SKUs and the loyalty is product-based rather than tinting-machine-based. Whether that holds when a Birla machine sits next to an Indigo display is the open question of FY27.

The honest read of where Indigo is, then, is somewhere in between Jalan’s confidence and the bears’ alarm. No one’s profitability has been destroyed yet — Jalan is right about that. But the growth rate is now mid-single-digit instead of high-teens, which is a different kind of damage that takes longer to show up in the same line. Volume growth in Q3 FY26 was barely positive on the volume-heavy putty and cement-paint category. Mix shift toward higher-realisation premium emulsion and enamel is doing more of the work than units shifted. The cycle is not catastrophic. It is, however, a long quiet attrition that asset managers do not always price patiently.

The Q3 FY26 print

Standalone revenue in Q3 FY26 came in at Rs 338.9 cr, up 3.5% year on year. Below the company’s own guided growth aspiration, and below what the brokerage community had been triangulating to in mid-quarter. October 2025 was a soft month industry-wide because of a delayed monsoon withdrawal and an early Diwali, both of which compressed the painting season. By December the run-rate had recovered. Consolidated revenue was Rs 358.8 cr (+4.7%), with Apple Chemie contributing Rs 20 cr at 31.5% growth — about a third of the consolidated absolute growth despite being only about 5% of the revenue base.

The margin print is the part that surprised. Standalone EBITDA margin came in at 19.4%, the highest Q3 print since IPO, against 17.5% in the year-ago quarter. Standalone gross margin was 47.1%, against 47.2% the prior year — flat at a sector-leading level. Consolidated EBITDA margin was 19.0%. The drivers, in plain English, were three: gross margin held, raw-material tailwinds and premium-mix reinforcement keeping the per-litre realisation strong; operating leverage starting to show on the existing fixed-cost base; and — here is the caveat — A&P spending got cut hard. Advertising and promotion was 5.6% of revenue against 8.2% the year before. That single line is worth roughly 260 bps of EBITDA margin help. Which means roughly two-thirds of the year-on-year EBITDA margin lift was Indigo dialing back ad defence rather than the underlying franchise running hotter.

That isn’t necessarily a bad signal — A&P had been propped up a year earlier specifically to defend mindshare against Birla’s hoarding-blanket campaign — and the demand was clearly still arriving without the ad support, which is what Q3’s 3.5% growth implies. But it does mean the Q3 number is not a clean read on franchise strength. If Birla’s new CEO ramps spending again in FY27, Indigo will be forced to re-up its A&P, and a 19.4% margin reverts toward 17-17.5%. The Q3 print, in that read, is the peak rather than the new baseline.

The other story sitting inside the quarter is the Jodhpur water-based plant. The 90,000 KLPA plant was originally guided for Q3 FY26 commissioning. The actual commercial production date, per the Q3 FY26 investor presentation, is now June 2026. The 12,000 KLPA solvent-based unit and the brownfield putty expansion are already operational. The water-based plant matters because emulsions are the high-margin growth segment — adding 90,000 KLPA roughly doubles Indigo’s water-based capacity and de-bottlenecks growth in exactly the segment Birla is most aggressive in. The catch is that any new paints plant runs at 25-35% utilisation in year one, which means the plant is dilutive to consolidated ROCE through FY27 before becoming accretive in FY28-29 if utilisation builds toward 60-70%. The year-one P&L impact is probably 150-200 bps of EBITDA margin headwind from depreciation and plant overhead before utilisation catches up. Management has not guided this explicitly. The bull case for FY27 is that volume catches up to capacity faster than expected because emulsion demand recovers; the bear case is the plant runs at 25% all year and pulls reported margins back to 17-18%.

Apple Chemie, the embedded option

In April 2023, Indigo paid roughly Rs 80-90 cr to acquire 51% of Apple Chemie India Pvt Ltd, a Pune-based waterproofing and construction-chemicals company. The original Apple Chemie promoters retained 49% and continued to run the operating business. The structure is unusual for an Indian listed acquirer — most paint companies that buy adjacencies move to full ownership within a quarter or two — and Jalan has been deliberate about not pushing for it. On the Q2 FY26 call he said the business was extremely well run by the current promoters, that he had no plans for full acquisition, and that the existing stakeholders would maintain motivation through their ownership stakes. The intent, in other words, is to leave them alone for the foreseeable future and let cross-sell synergies through the dealer channel do their slow work.

The numbers, even small, are the most interesting in the entire Indigo P&L. FY25 revenue was Rs 63.7 cr, up 20.6% year on year. The first nine months of FY26 ran Rs 47.6 cr; Q3 FY26 alone was Rs 20 cr at 31.5% growth. The exit run-rate by FY26-end is Rs 80-85 cr, which makes FY27 plausibly a Rs 105-110 cr business if growth holds. Standalone economics, per management commentary, are below Indigo standalone’s — EBITDA margin in the low-mid teens against Indigo’s 18-19%, attributable to what management has called adverse product mix. That is partly diplomatic — Pidilite (Dr Fixit) and Berger Construction Chemicals are defending their territory aggressively, which means the price ladder in waterproofing is steeper than Indigo first modelled. The Apple Chemie business is roughly an Rs 8-10 cr EBITDA contribution in FY26, against ~5% of consolidated revenue, so call it 4-5% of consolidated EBITDA today.

The strategic logic was always clean. Construction chemicals — waterproofing, tile adhesives, repair compounds, sealants — is the segment Pidilite owns through Dr Fixit at a multiple that paint companies do not get. It’s a B2B-flavoured category with infrastructure-spend tailwinds, sticky ticket sizes, and the same dealer who sells decorative paint. Indigo’s logic in buying in is to cross-sell through the existing dealer network and ride India’s infra cycle. The theory is reasonable; execution is still early.

The reason Apple Chemie matters more than its current 5% suggests is what it does to Indigo’s valuation in three years. Growing at 30%+ against the parent at 4-5%, Apple Chemie’s share of consolidated revenue compounds quickly: 5% to 7% to 9% to 12% over three years on flat parent growth. By FY28, plausibly, Apple Chemie is 10% of revenue and 8-10% of EBITDA. At that point the right way to value Indigo stops being “paints company at a paints multiple” and becomes paints at the paints multiple plus Apple Chemie at a Pidilite-adjacent multiple — call it 35-45x. Today, no — at 5% of revenue and a low-teen EBITDA margin, it is noise inside the consolidation. But it is the embedded option that the standard sector lens tends to miss. The call you’d make on Indigo three years out, if Apple Chemie has scaled the way the run-rate suggests it will, is materially different from the call you’d make if you treat the company as a small paint maker with a side hobby.

Margin quality at small scale

The persistent question, the one that comes up on every concall and every brokerage initiation note, is how Indigo sustains a 19% standalone EBITDA margin on a tenth of Berger’s revenue. APL sits at 17-18% post-derate. Berger at 18%. Kansai in the mid-teens. Indigo, the smallest of the listed names, is roughly 1-2 ppt below Berger and 2-3 ppt below APL post-derate — but there’s no obvious reason in the textbook for a sub-scale player to be running margin at all close to the leaders. It usually doesn’t. Why does this one?

Three reasons, of which the first two are durable and the third is a lever rather than a moat. The first is mix. Sixteen per cent of revenue in emulsions sounds small, but within emulsions Indigo’s premium-emulsion share is heavy — Hemant Jalan has consistently steered the price-points up rather than in. On putty and cement paints, which are 43-47% of revenue and ostensibly lower-margin, Indigo’s pricing is differentiated through premium distemper colours and branded ceiling paint, rather than running pure commodity. So compared to Kansai, where the auto-coatings business runs at high-teens EBITDA but is a volume-deflated commodity drag, Indigo’s mix is better positioned within its own segment than the headline category map would suggest.

The second is pricing discipline. Jalan has been explicit on every concall that Indigo will not price-cut to chase volume. The “I’d rather sacrifice a percentage point of GM through targeted trade discounts than cut price” formulation is, in margin terms, a defence of the gross-margin floor. Trade discounts pull cost into the SG&A line; price cuts pull it into the gross margin line. The first is reversible quarter-on-quarter; the second tends to be sticky.

The third is A&P spend below peers. APL runs at 6-7% of sales, Berger 5-5.5%, Birla obviously much higher in launch year. Indigo was at 7-8% during the Birla scare; in Q3 FY26 it dropped back to 5.6%. This is the marginal lever — Indigo doesn’t need to spend like APL because it is targeting a narrower geographic and product slice. A&P discipline here is a function of strategy rather than brand strength alone, which means that if competitive pressure forces it back up, the margin gives back exactly what the lever was funding.

What would compress all three together? A genuine dealer-share war where Indigo has to match Birla’s incentives rupee-for-rupee, which would take 200-300 bps off gross margin. A sustained crude or TiO2 spike — the current snapshot is Brent at $105 and TiO2 turning up from January — that the trade can’t absorb a price hike against. Or a slow weakening of differentiated-SKU pricing power as Birla and JSW Dulux backfill those niches over time. The honest read: 19% is sustainable in the steady state. It is not sustainable if Birla launches a Tier-3 push or if APL rebuilds rural-distemper attention that they had let drift.

The acquisition target question

The cap structure invites the question even when no one is publicly speculating about it. Market cap Rs 4,100 cr at 24 April 2026. Promoter holding 53.88%. A controlling stake — 50% plus one share — at a 30% premium to spot is a Rs 3,500 cr cheque. Small enough that JSW, Pidilite, Reliance Retail, or Tata Consumer could write it from petty cash. Birla itself, as a defensive consolidation play, would be plausible at Rs 5,000-6,000 cr.

Jalan has said nothing on record about being a willing seller. He is 65, founder, highly identified with the company. The 53.88% holding has been broadly stable since the IPO. There has been no obvious distress trigger. In November 2025 the stock jumped 20% over two days and the exchanges sought clarification — which sounds like the kind of move that signals takeover rumour but in fact turned out to be Q2 FY26 results being unexpectedly strong. Revenue +4.2% YoY, the highest in four quarters. EBITDA +12.1%, the best in six. Earnings, not a deal. (Caveat: I could not find Indigo’s response to the exchange’s clarification request, so cannot rule out that takeover speculation traded on the day.)

In the strategic-fit ladder, JSW is the most coherent buyer. JSW already bought Akzo Nobel India in December 2025 to create JSW Dulux. Indigo plus Dulux gives JSW the Tier-3/4 brand it does not yet have, paired with a metropolitan premium brand. Pidilite is the next plausible name — Apple Chemie alone might be the lure, given that Pidilite competes head-to-head in waterproofing. Less clear whether Pidilite would want the parent paints business, given they are not paints-native. Aditya Birla, as a defensive buy, is structurally possible but less likely because Birla’s strategy has been organic capacity-led rather than M&A-led. Reliance and Tata Consumer would be financial-investor logic with no obvious paint synergy.

The recent strategic-paints M&A reference is the Akzo deal, which closed at roughly 25x EV/EBITDA. At Indigo’s TTM EBITDA of Rs 247 cr and current EV of Rs 3,800 cr (consolidated), Indigo trades at roughly 15x. A control bid at 25x EV/EBITDA implies an EV of Rs 6,175 cr and a per-share price of about Rs 1,300 — roughly 50% above the 24 April 2026 price. SEBI’s takeover code mandates a minimum open offer of 26% additional from public float at a price set by 60-day VWAP and recent acquisitions, so minorities would receive the open-offer price, which would normally be the deal price. In a Rs 1,300 scenario, that is a 50% premium for non-promoter shareholders.

The bear case to that whole structure is the more honest one. Jalan is past 65. The likeliest exit for a founder of his profile is not a 50% premium fire-sale in the heat of a strategic auction; it is a quiet block deal at a market-context multiple to a single strategic buyer. Akzo went at 25x because Akzo had European exit dynamics and a free-tinting-machine arms race forcing the seller’s hand. Jalan has neither. A Rs 950-1,000/share offer to a willing seller, against a mostly stagnant share price since IPO, is the realistic strategic-buyer scenario. Minorities collect a thin 10-15% premium that erases two years of share-price drift but doesn’t really compensate for the time-value of capital lock-up. There is something in the current price that already reflects the Akzo precedent — the upside if a deal happens is real but capped, and the downside if no deal happens for years is the multiple drifting back to standalone-paints fair value.

I cannot put a probability number on this. There is no reported speculative noise. But the structure invites the question and the Akzo precedent makes the acquirer set walk the hallway with a model in hand.

Capital allocation and what the founder actually does

The thing to keep in your eye, when you are looking at a small-cap with a long-tenured founder-CEO, is whether the cash that the business throws off goes back into the business or somewhere that ought to make you nervous. Indigo’s reads as the first kind. Net cash always — FY25 closed with borrowings of Rs 27 cr against cash and equivalents of Rs 258 cr. CFO/EBITDA at 88-89%, close to Berger’s and better than Kansai’s. FY25 capex of Rs 178 cr on the Jodhpur plant build-out was funded entirely from internal accruals. The only material acquisition has been Apple Chemie — small, structured to keep the original promoters running their business, no debt-financed dynasty buildout, no Goa hotel, no Jaipur land bank. The FY24 annual report disclosed no significant related-party transactions, and the SES proxy advisory report from August 2024 was clean — no flagged concerns on RPTs, executive compensation in line with peers, board composition adequate for a recently-listed company.

ROCE has dropped from 22.8% in FY24 to 19.0% in FY25, but that is a mix of the slow demand environment and the Jodhpur capacity build (gross block went up faster than sales, which is what happens when you put up a plant before utilisation arrives) — not a leveraged-up balance sheet or value-destructive M&A. The capex is creating real assets that, once utilised, should improve ROCE again from FY28-29. CFO conversion has stayed firm.

The one thing I cannot verify without the FY25 annual report in hand — and it is the thing that ought to be tracked — is whether Jalan has begun any inheritance or promoter-pledging activity. The 53.88% promoter holding is comfortably above the SEBI control threshold but not at the 65-75% comfort zone that signals total commitment. Some equity has been used to reward management ESOPs and to absorb minor dilutions. The trajectory is not concerning yet. It is worth tracking.

What the valuation actually says

Indigo trades at 27.6x trailing P/E on the consolidated entity, per Screener as of 24 April 2026. This is the cheapest the stock has been since the IPO. The P/E peaked above 90x in 2021 and has been progressively de-rating with growth deceleration. EV/EBITDA in the 14-17x range depending on cash treatment — call it 16x as the conservative read. P/B at 4.35x, reasonable for an asset-light branded business — below APL’s roughly 11.6x, below Berger’s 8.6x, above Kansai’s 2.5x. Among the listed peers, Indigo and Kansai are the only two that don’t carry a 50x-plus P/E multiple. APL is around 55x. Berger 52x.

The PEG number is ugly on a single trailing year. Indigo’s near-term growth is mid-single-digit and the multiple is 27.6x, which gets you a PEG north of 11x by some screens. That is a notoriously unstable measure for small-caps in cyclical troughs. On the 5Y revenue CAGR of 7.3%, PEG comes out to roughly 3.8x — comparable to APL’s. Compared to Berger at 52x with 5-7% growth (PEG 7-9x), Indigo is meaningfully cheaper on a PEG basis even with the small-cap discount. PEG is not the right anchor here.

The right anchor for a small-cap niche player is probability-weighted scenario value rather than a single multiple. In the bull case (35% weight), Apple Chemie compounds at 30%+, paints volume re-accelerates to high single digits as Birla’s CEO transition slows their burn, EBITDA margin holds at 18-19%, and Jodhpur ramps. FY28E EBITDA Rs 350 cr at a 22x multiple gives an EV of Rs 7,700 cr, or roughly Rs 1,620 a share. In the base case (40% weight), paints grow 4-6% and Apple Chemie 25-30%, with EBITDA margin 17-18%. FY28E EBITDA Rs 290 cr at 16x gives an EV of Rs 4,640 cr, or Rs 970 a share. In the bear case (25% weight), Birla doubles down post-CEO-change, dealer pressure starts to bite, EBITDA margin compresses to 15%, growth flatlines. FY28E EBITDA Rs 230 cr at 11x gives an EV of Rs 2,530 cr, or Rs 530 a share. Probability-weighted, that’s about Rs 1,030 — a modest premium to the spot price of Rs 860.

The acquisition tail sits on top of that. If a Rs 1,300/share strategic bid lands within 24 months, the weighted return shifts to roughly a 30% IRR. If no bid arrives and the bear scenario plays out, you’re looking at -15% IRR.

Where I land is: fairly priced for the base case, cheap if Apple Chemie and Jodhpur deliver, with a real acquisition tail. Not a screaming buy at Rs 860, but not overpriced either. The thesis is more about asymmetry than absolute valuation.

The argument against

The cleanest counter-thesis is the demand one. Rural wage growth has run under 1% real CAGR since FY15. Distemper and cement-paint volume in Q4 FY25 was down 10.3%. Indigo’s product mix is 43-47% in the slowest-growing category in the worst rural cycle in a decade. The differentiated-SKU story is clever, but doesn’t help if the underlying customer is not repainting. Indigo’s strategy positions it correctly in a buoyant rural cycle and incorrectly in a stagnant one. The macro is in the second.

Layer onto that the dealer-channel pressure from Birla, who can outspend Indigo on incentives and tinting machines, and the reason Indigo’s dealer count is still growing slowly is not that Birla is failing to take dealers — it is that Birla is taking dealers Indigo never had, while Indigo continues to add at the perimeter. When the slowdown bites harder, dealers who must choose between the cash-incentive Birla relationship and the high-margin Indigo display will keep the cash. The risk shows up as FY27 churn rather than FY26 levels. A Q3 FY26 margin lift that is two-thirds A&P cut rather than franchise strength is the same observation in a different colour — if Birla forces the spending back up, the 19.4% reverts to 17-17.5%, and the multiple should come down with it.

Apple Chemie is the third worry. Thirty-per-cent revenue growth on a low base with thin EBITDA margin is real but not dispositive. The “adverse product mix” language on the concalls flags that price competition is starting in waterproofing too, especially as Pidilite and Berger Construction Chemicals defend their territory. Apple Chemie may compound revenue handsomely while staying structurally lower-margin than the parent for years.

The Jodhpur plant is the fourth. A new 90,000 KLPA water-based plant at 25-30% utilisation drags consolidated EBITDA margin and ROCE for at least two years. The market may not price it patiently. If FY27 reported margins tick down because of new-plant overhead and Birla-related dealer spending at the same time, the stock could re-rate to 20-22x P/E rather than the 27.6x it’s at now — that’s a 25% derate before any business-quality concerns get a chance to play out.

And the fifth is the founder-exit scenario in the form most likely to actually happen — a quiet block deal to a strategic at 15-18x EV/EBITDA, below the Akzo comp, because the buyer is strategic enough to walk if they have to and Jalan is past 65 and ready to hand off. A Rs 950-1,050/share bid in that scenario is only 10-22% above current. Minorities collect a thin premium and lose the optionality of the founder-led story.

Stack the bear arguments and you get a Rs 530-600 outcome over two to three years — an outright loss against the current Rs 860.

The standard sector lens, where it breaks

Three places, in order of importance. First, the Apple Chemie strip — standard peer comparison treats Indigo as a paints company. Once Apple Chemie crosses 8-10% of revenue, around FY28, it should be valued separately at construction-chemicals multiples. Pretending it isn’t there understates Indigo’s value by 5-10% today and 15-20% in three years. Second, dealer count. The standard sector lens reads 19,134 against APL’s 70,000 and concludes Indigo’s distribution is one-quarter of APL’s commercially relevant strength. The right metric is dealer productivity in Indigo’s chosen geographies, not absolute count. In Indigo’s home turf — Rajasthan, MP, Bihar, eastern UP — Indigo is plausibly second or third in dealer mindshare, which is what matters for share-of-wallet. Third, the multiple. PEG on the trailing year is too punitive (the cycle is at trough); absolute P/E is too generous (the small-cap discount applies). The right valuation lens is the probability-weighted scenario approach above, plus a separate option-value computation for a strategic acquisition. Single-multiple comparisons break because Indigo’s value has fat tails that Berger’s and APL’s don’t.

What would change the thesis

A bullish trigger arrives if Apple Chemie crosses Rs 100 cr revenue with EBITDA margin above 15% (likely H1 FY27); if Jodhpur reaches 50% utilisation in 12 months; if Indigo files for a separate listing of Apple Chemie within 3 years; or if a strategic bid lands at greater than 25x EV/EBITDA. A bearish trigger arrives with two consecutive quarters of dealer-count decline; gross margin dropping below 45%; A&P spending forced back above 8% to defend share; a profit warning attributed specifically to Birla competition; or promoter-pledge or unusual stake-reduction activity.

What I couldn’t get to

I worked off concall transcripts, press notes, and brokerage summaries rather than a direct read of the FY25 annual report. The full RPT and segment-disclosure tables would be the right thing to confirm before adding capital. Specific Apple Chemie EBITDA margin disclosure is inferred from concall directional commentary rather than a published figure. Indigo’s response to the November 2025 BSE/NSE clarification on the share-price spike — a non-response is fine, but I couldn’t confirm it. Volume mix split FY26 by SKU is not published by Indigo and the brokerage notes don’t reconstruct it. A clean Birla Opus FY26 dealer-overlap dataset for Indigo’s home geographies would substantially de-risk the dealer-channel-pressure red-team.

The metrics, in one place

#MetricConsolidated FY25Standalone FY25
1Revenue (Rs cr)1,340.71,277.2
2Revenue 3Y CAGR (FY22→FY25)~10.2%~9.5%
3Gross margin~46.1%46.5%
4EBITDA margin17.4%18.1%
5EBITDA margin trajectory FY22→Q3 FY2614.5% → 17.0% → 18.2% → 17.4% → 19.0%15.0% → 17.5% → 18.5% → 18.1% → 19.4%
6ROCE19.0% (FY24: 22.8%)~19.5%
7ROE14.6%~15.1%
8CFO/EBITDA~88%~89%
9Working capital days36~34
10Net Debt/EquityNet cash (Rs 27 cr borrow / Rs 258 cr cash)Net cash
11P/E TTM (24 Apr 2026)27.6xn/a
12EV/EBITDA TTM~14-17xn/a

Q3 FY26 print: standalone revenue Rs 338.9 cr (+3.5% YoY), EBITDA Rs 65.6 cr (+14.5%), EBITDA margin 19.4%, gross margin 47.1%; consolidated revenue Rs 358.8 cr (+4.7%), EBITDA Rs 68.3 cr (+19.5%), EBITDA margin 19.0%, PAT (ex-exceptional) Rs 41.7 cr (+16.4%); Apple Chemie Rs 20 cr (+31.5%). A&P 5.6% of revenue (vs 8.2% YoY), 9M FY26 5.9% (vs 7.0% prior). Dealers 19,134 (Dec 2025), tinting machines ~11,900, depots 55, plants 5 (rising to 6 by mid-CY26).

And so

Indigo Paints in 2026 is a single decision compounding for twenty-five years. Hemant Jalan, IIT Delhi chemical engineer, walked out of a Vedanta copper smelter in 1999 and chose to build a paint company in a town no one would have picked, in the kind of shade-and-finish corners of the market that the majors had decided were too small to fight in. He kept making that choice — the same choice — through the calcium chloride detour, the fourteen-year bootstrap, the Sequoia round, the IPO, and now the Birla-Opus stress test. The choice has worked because the layer he picked stayed unfished, and because his unit economics on those odd corners have been generous enough to the dealer to keep the relationship sticky for fifteen years.

The interesting question for the next three years isn’t whether Indigo can grow. It is whether the layer stays unfished. The standard sector lens, which reads dealer count and emulsion exposure and concludes that Indigo is a sub-scale also-ran, misses the part where Indigo has the highest gross margin in the listed peer set and the second-highest EBITDA margin on a tenth of Berger’s revenue, and where Apple Chemie is compounding 30%-plus inside the consolidation at a multiple no one is ascribing to it. The bear case, which reads the rural-wage cycle and Birla’s tinting-machine fleet and concludes that Indigo’s structural disadvantages are about to bite, is also reading something real — the Jodhpur plant will be dilutive in FY27, the Q3 FY26 margin lift was partly an A&P cut, and the founder is 65 with 53.88% of the equity in his own name.

Both reads are right. The thing they have in common is a man, age 65, in his twenty-fifth year as founder-CEO, on a January concall, telling a sell-side analyst he has space to sacrifice a percentage point of gross margin and still walk out with the highest in the industry. The interesting question is not whether he is right. It is whether, when the next test arrives, he is still the one making the choice.

Sources